Axon Enterprise, Inc $AXON Shares Purchased by S Bank Fund Management Ltd

Key Points

• S Bank Fund Management Ltd increased its stake in Axon Enterprise by 290.5% during the 2nd quarter, owning 3,522 shares valued at approximately $2.9 million.
• A majority of analysts hold a consensus rating of "Moderate Buy" for Axon Enterprise, with a target price averaging $841.64.
• Axon Enterprise reported a 32.6% increase in quarterly revenue year-over-year, achieving $668.54 million against expectations of $641.77 million.

S Bank Fund Management Ltd raised its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 290.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,522 shares of the biotechnology company's stock after buying an additional 2,620 shares during the period. S Bank Fund Management Ltd's holdings in Axon Enterprise were worth $2,916,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. TCTC Holdings LLC increased its stake in Axon Enterprise by 75.0% during the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock valued at $29,000 after buying an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC grew its stake in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 33 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of Axon Enterprise in the 1st quarter worth approximately $31,000. Catalyst Capital Advisors LLC acquired a new position in shares of Axon Enterprise in the 1st quarter worth approximately $32,000. Finally, Flaharty Asset Management LLC acquired a new position in shares of Axon Enterprise in the 1st quarter worth approximately $33,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings reiterated a "hold (c)" rating on shares of Axon Enterprise in a report on Wednesday, October 8th. Raymond James Financial reiterated an "outperform" rating and issued a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Northland Securities set a $800.00 target price on shares of Axon Enterprise in a report on Tuesday, August 5th. Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the stock an "overweight" rating in a report on Friday, July 11th. Finally, Wolfe Research assumed coverage on shares of Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating for the company. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus target price of $841.64.

Axon Enterprise Stock Performance

AXON stock opened at $644.99 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The stock has a market cap of $50.63 billion, a P/E ratio of 159.26, a P/E/G ratio of 27.36 and a beta of 1.41. The firm has a 50 day simple moving average of $747.25 and a 200 day simple moving average of $715.49. Axon Enterprise, Inc has a 52 week low of $422.38 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm's quarterly revenue was up 32.6% compared to the same quarter last year. During the same period last year, the company posted $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $831.29, for a total transaction of $8,312,900.00. Following the transaction, the chief executive officer owned 3,053,982 shares of the company's stock, valued at approximately $2,538,744,696.78. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey C. Kunins sold 7,891 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the transaction, the insider directly owned 144,538 shares in the company, valued at approximately $108,417,953.80. The trade was a 5.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,932 shares of company stock valued at $45,115,616. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.